News

Fierce Pharma4h
Fierce Pharma Asia—China biotech deal boom; Takeda's narcolepsy win; Sino Biopharm's LaNova buyout
Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...
Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer
Bristol Myers Squibb (NYSE:BMY) announced on Friday that its anemia therapy, Reblozyl, developed with Merck (NYSE:MRK), did ...
BioPharma Dive40m
Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel
The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...